TP53 and cancer: In addition, the binding site for the peptide, the tetramerization domain of p53 (aa 320–353), is rarely mutated in human cancer with mutant p53, thus allowing the peptide the ability to restore a WT p53 phenotype in a large number of p53 mutant cell lines.